PARP1 and neoplasm: PARP1/2 inhibitors were first approved for the treatment of breast and ovarian cancers [8, 13], and subsequently, many in vitro and in vivo studies have been conducted to investigate their efficacy in other tumor types, although without any satisfactory progress, which is partially due to mutations that affect the DDR-associated genes, which are not common in other malignancies, including AML [9, 12, 13, 15].